Precision Diagnostics for Definitive Clinical DecisionsMolecular Oncology
Connecting morphology, biomarkers and molecular information to support increasingly precise cancer classification and treatment planning.
What is molecular oncology?
Molecular oncology examines genetic or molecular features of tumours that may support classification, prognostic assessment, treatment selection or other clinically relevant decisions.
When may molecular testing be considered?
- Specific tumour biomarkers
- Therapy-selection questions
- Classification of selected tumours
- Confirmation of molecular alterations
- Cases where IHC and morphology indicate further testing
- Research and advanced oncology pathways
Integrated diagnostic workflow
Morphology → IHC → molecular question → specimen adequacy review → molecular assay → result verification → integrated report.
The molecular test should be selected in context; not every tumour requires molecular testing.
Specimen considerations
Tissue quantity, tumour content, preservation, fixation, nucleic-acid quality and the specific assay all influence test suitability. Some molecular pathways may use tissue while others may use other specimen types where validated and clinically appropriate.
Molecular reporting
Results should be reported with the relevant alteration/biomarker, test limitations and appropriate clinical context. Molecular findings should be interpreted by qualified professionals within the patient's broader diagnostic and clinical picture.
Future expansion
PATHOSURE®'s digital roadmap includes molecular workflows, NGS integration, variant reporting, external molecular laboratory interfaces and bioinformatics integration.
